Trials / Completed
CompletedNCT00016965
BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Every 21 Days in Patients With Advanced Pancreas Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- SWOG Cancer Research Network · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced pancreatic cancer.
Detailed description
OBJECTIVES: * Determine the 6-month survival rate and time to treatment failure in patients with advanced pancreatic adenocarcinoma treated with BMS-247550. * Determine the frequency and severity of toxic effects of this drug in these patients. * Determine the complete and partial response in those patients with measurable disease treated with this drug. * Determine the pharmacokinetic profile of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive BMS-247550 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients are followed every 6 months for 2 years and then annually until 3 years after registration. PROJECTED ACCRUAL: A total of 25-55 patients will be accrued for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ixabepilone |
Timeline
- Start date
- 2001-07-01
- Completion
- 2006-04-01
- First posted
- 2003-01-27
- Last updated
- 2013-06-24
Locations
95 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00016965. Inclusion in this directory is not an endorsement.